By Laura Rauw, Medical Reporter, U.S. Department of Labor Department of Health and Human Services, U, June 21, 2018 Dr. Jules Valesic and her colleagues at the University of California San Francisco (UCSF) have announced they will be the first to offer the world’s first vaginal rejuvenation treatment for female breast reconstruction.
The surgery, which involves the removal of a breast and replacing it with an external, implantable breast implant, is a first in its kind.
Dr ValesIC and her team will provide the first vaginal implant to women in the United States who are at a high risk for breast cancer.
Dr Valesics coauthors the article, published in the journal Plastic Surgery.
The U.K.-based team of doctors, led by Dr. Raula Valesico, the director of UCSF’s Breast Reconstruction Program, performed the surgery on three women with metastatic breast cancer in the Los Angeles area.
“The implant is an excellent device, and it is safe, comfortable, and well tolerated, which is why it was selected for this treatment,” Dr. Valesi said in a statement.
“It is also an effective and safe way to restore the quality of life for those women who are currently struggling with breast cancer.” “
We believe that the vaginal rejuvenator is the most appropriate way to stimulate the regeneration of breast tissue after breast cancer has already been removed,” she continued.
“It is also an effective and safe way to restore the quality of life for those women who are currently struggling with breast cancer.”
The UCSF study, which was funded by the National Institutes of Health, involved six women who were treated for breast and ovarian cancer.
They received either a total mastectomy, or bilateral mastectomy (both breast implants), to remove the tumors and a total implant of a “chemo-compatible” breast.
Both procedures were performed in collaboration with Dr. Srinivasan.
The three women who received vaginal rejuvenators also had a second surgery to replace the breast implant.
They did not receive any mastectomy.
“There are a number of women with ovarian cancer and breast cancer who will benefit from this procedure and we will see if this will be a success for them,” Dr Vilsic said.
“We also want to stress that the surgery was not only safe and efficient, but it was also completely reversible and had no side effects,” she added.
“In fact, after the operation, they had no lingering side effects, and they were able to return to normal functioning in the same way as before the surgery.”
The U.N. World Health Organization has declared that breast cancer is a global public health emergency and has said that this surgery should be considered for women with a breast cancer diagnosis who are not at a higher risk of recurrence.
“It is important to note that the surgical and surgical-related complications from vaginal rejuvenating are not life-threatening,” Drs Valesici and Rauws said.
“However, the surgery may also result in breast cancer recurrence.”